MedTrace Logo

Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX

NCT03555123 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2021-05-11

No results posted yet for this study

Summary

A randomized, double-blind, Multicenter, parallel, placebo-controlled study

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

Simdax

Levosimendan2.5mg/ml

Sponsors & Collaborators

  • Yooyoung Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Suck-min Kang, MD.PhD. · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-11
Primary Completion
2022-01-30
Completion
2022-07-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03555123 on ClinicalTrials.gov